Ra Pharmaceuticals has appointed Simon Read as chief scientific officer and bringing more than 20 years of drug discovery and development experience including, leadership roles of increasing responsibility at GlaxoSmithKline, AstraZeneca, Roche/Genentech and Grunenthal GmbH. During this period, Dr. Read has worked on the clinical development of some of the most well-known, breakthrough drugs in the immunology area, including Rituxan (ritxumab) and Actemra (tocilizumab). Most recently, he served ...